stacking tirzepatide and semaglutide Structural insights into multiplexed pharmacological actions of peptide 20 at the GIP, GLP-1 or glucagon receptors Tirzepatide vs. Semaglutide: A Complete
Description
World Diabetes Day reminds us that diabetes isnt just about sugar - its about how our body uses energy
A selection of trust tools and treatments
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Prospective ultrasound studies show a higher prevalence of residual gastric content in GLP-1 RA users, particularly during dose escalation or when GI symptoms are present
Free consult!
It comes after Diabetes UK revealed obesity has fuelled a 39 per cent spike in the condition among the under-40s.
